HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Armando Santoro Selected Research

ARQ 197

1/2019Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
1/2019Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
1/2018Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
2/2017Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.
11/2016Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
8/2015Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
3/2015Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
2/2015Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
4/2014Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.
2/2013Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Armando Santoro Research Topics

Disease

127Neoplasms (Cancer)
06/2022 - 01/2002
47Hodgkin Disease (Hodgkin's Disease)
01/2022 - 09/2006
43Breast Neoplasms (Breast Cancer)
09/2022 - 01/2003
39Hepatocellular Carcinoma (Hepatoma)
11/2021 - 09/2006
34Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 08/2003
32Disease Progression
01/2022 - 01/2002
23Neoplasm Metastasis (Metastasis)
12/2020 - 05/2004
20Lymphoma (Lymphomas)
12/2022 - 04/2002
18Malignant Mesothelioma
01/2022 - 03/2006
15Neutropenia
02/2022 - 07/2008
15Colorectal Neoplasms (Colorectal Cancer)
01/2021 - 07/2004
14Sarcoma (Soft Tissue Sarcoma)
10/2020 - 04/2008
12Diarrhea
08/2020 - 09/2006
11Fatigue
01/2021 - 09/2006
10COVID-19
11/2022 - 07/2020
9Glioblastoma (Glioblastoma Multiforme)
06/2021 - 02/2007
7Glioma (Gliomas)
02/2022 - 02/2007
7Brain Neoplasms (Brain Tumor)
06/2021 - 08/2003
7Exanthema (Rash)
01/2021 - 04/2005
6Thymoma (Thymic Carcinoma)
01/2022 - 03/2009
6Hypertension (High Blood Pressure)
11/2021 - 01/2009
6Abdominal Pain (Pain, Abdominal)
01/2018 - 01/2009
5Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022 - 08/2003
5B-Cell Lymphoma (Lymphoma, B Cell)
01/2022 - 04/2005
5Pneumonia (Pneumonitis)
01/2022 - 01/2018
5Nausea
11/2021 - 05/2010
5Fibrosis (Cirrhosis)
01/2021 - 03/2011
5Spinal Cord Compression
05/2012 - 01/2010
5Thrombosis (Thrombus)
11/2006 - 02/2003
4Mesothelioma
06/2022 - 07/2008
4Triple Negative Breast Neoplasms
06/2022 - 01/2016
4Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2022 - 01/2012
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2022 - 04/2011
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 01/2002
4Cardiotoxicity
01/2021 - 10/2013
4Peripheral Nervous System Diseases (PNS Diseases)
01/2021 - 05/2010
4Infections
08/2020 - 01/2006
4Lymphatic Metastasis
01/2020 - 04/2007
4Vomiting
12/2014 - 05/2010

Drug/Important Bio-Agent (IBA)

34Sorafenib (BAY 43-9006)FDA Link
01/2021 - 09/2006
21Biomarkers (Surrogate Marker)IBA
11/2021 - 09/2006
18Pharmaceutical PreparationsIBA
06/2022 - 06/2005
15PlatinumIBA
01/2022 - 06/2007
15Cisplatin (Platino)FDA LinkGeneric
01/2020 - 05/2004
13Immune Checkpoint InhibitorsIBA
06/2022 - 12/2016
13Pemetrexed (MTA)FDA Link
01/2022 - 03/2006
13NivolumabIBA
01/2022 - 09/2016
13Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2021 - 01/2015
13ErbB Receptors (EGF Receptor)IBA
01/2019 - 08/2003
12Doxorubicin (Adriamycin)FDA LinkGeneric
11/2021 - 05/2004
11ARQ 197IBA
01/2019 - 01/2013
10GemcitabineFDA Link
10/2021 - 01/2007
9Brentuximab VedotinIBA
01/2022 - 08/2013
9DNA (Deoxyribonucleic Acid)IBA
01/2021 - 03/2010
9IfosfamideFDA LinkGeneric
12/2019 - 04/2002
8Tyrosine Kinase InhibitorsIBA
06/2020 - 08/2005
7Phenobarbital (Luminal)FDA Link
06/2022 - 01/2020
7pembrolizumabIBA
01/2022 - 01/2017
7Vinorelbine (Navelbine)FDA LinkGeneric
01/2022 - 01/2003
7Trastuzumab (Herceptin)FDA Link
11/2021 - 02/2006
7AnthracyclinesIBA
06/2021 - 01/2006
7Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2019 - 08/2005
6regorafenibIBA
01/2022 - 11/2013
6LigandsIBA
12/2021 - 09/2016
6Bendamustine HydrochlorideFDA Link
11/2021 - 09/2011
6Proteins (Proteins, Gene)FDA Link
04/2015 - 09/2010
5Hormones (Hormone)IBA
02/2022 - 11/2010
5Rituximab (Mabthera)FDA Link
01/2022 - 09/2003
5copanlisibIBA
11/2021 - 12/2017
5Temozolomide (Temodar)FDA LinkGeneric
06/2021 - 02/2007
5Monoclonal AntibodiesIBA
01/2021 - 08/2005
5liposomal doxorubicin (Doxil)FDA Link
10/2020 - 01/2003
5Cetuximab (Erbitux)FDA Link
06/2019 - 07/2004
5Docetaxel (Taxotere)FDA Link
03/2019 - 05/2008
5Carboplatin (JM8)FDA LinkGeneric
03/2019 - 04/2005
5Phosphotransferases (Kinase)IBA
01/2019 - 09/2006
5thiamine triphosphorate (TTP)IBA
07/2013 - 09/2006
5Warfarin (Coumadin)FDA LinkGeneric
01/2006 - 02/2003
4Biological ProductsIBA
01/2022 - 06/2015
4alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2021 - 07/2012
4Imatinib Mesylate (Gleevec)FDA Link
01/2020 - 01/2005
4Lenalidomide (CC 5013)FDA Link
01/2020 - 01/2016
4TrabectedinIBA
01/2018 - 04/2014
4AntibodiesIBA
05/2016 - 03/2009

Therapy/Procedure

89Therapeutics
11/2022 - 08/2003
83Drug Therapy (Chemotherapy)
11/2022 - 01/2002
42Radiotherapy
11/2021 - 01/2002
32Stem Cell Transplantation
01/2022 - 02/2007
11Immunotherapy
06/2022 - 06/2015
10Hematopoietic Stem Cell Transplantation
01/2021 - 01/2007
8Adjuvant Chemotherapy
02/2022 - 01/2006
8Transplantation
01/2021 - 05/2009
8Haploidentical Transplantation
01/2021 - 01/2018
6Salvage Therapy
06/2021 - 07/2012
6Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
01/2020 - 07/2010
6Catheters
12/2017 - 02/2003
5Neoadjuvant Therapy
06/2022 - 01/2007
5Central Venous Catheters
12/2017 - 02/2003
4Autologous Transplantation
01/2020 - 05/2010
4Induction Chemotherapy
01/2020 - 04/2002